Tutorial: Multiplexing for Vaccine Development
Combination vaccines strain sample volume, immune response evaluation
If your work has anything to do with vaccine development, don’t miss this new tutorial in Genetic Engineering & Biotechnology News from Eric Shaw, head of clinical assay development at Takeda Vaccines. It’s an excellent insider’s view, replete with useful tips about how multiplexing makes it possible to conserve samples and discern immune subtleties.
As Shaw notes, there is mounting pressure for vaccine development pipelines to churn out combination and polyvalent vaccines, both of which are far more complicated to design and test than single-component vaccines. “There is tremendous public health value in creating combination and polyvalent vaccines, but scientists must consider potential challenges in assay development,” he writes. “Confirming immune responses to vaccines is far more complex when the vaccines incorporate multiple closely related antigens and when there is the potential for cross-reactivity among them.”
Address Development Challenges with Multiplexing
Multiplexing techniques, such as our xMAP® Technology, can address many of the development challenges posed by combination or polyvalent vaccines. “Compared to running a multitude of individual ELISA tests, multiplex assays are faster, more reliable, and more cost-effective,” Shaw reports. “This approach can streamline development of complex vaccines and bring products to market more quickly.”
In the tutorial, Shaw walks through many factors in the vaccine development process, highlighting the differences made by adopting multiplex technology. Sample volume is one of the most fundamental: because samples collected in clinical trials have limited volume, vaccine developers are faced with difficult choices. “Without multiplexing assays, scientists often must prioritize their testing schemes, eliminating certain useful biomarkers or analyses because there is not enough sample,” Shaw explains. “Multiplexing allows development teams to test more of the parameters they believe are relevant to vaccine evaluation, leading to the development of higher-quality vaccines with a more thorough understanding of their biological effects.”
“The efficiencies gained from multiplexing during both analytical and clinical trial phases of vaccine development can conserve resources and save time at multiple steps in development, reducing overall development times,” Shaw concludes. “The implementation of multiplex technology allows for significant progress in the development of complex vaccines.”
Click here to read the complete tutorial.
Learn More About xMAP® Technology
Luminex’s xMAP Technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities. Featuring a flexible, open-architecture design, xMAP Technology can be configured to perform a wide variety of protein or nucleic acid assays quickly, cost-effectively, and accurately.